{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:26Z","timestamp":1790719226707,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jhep.2013.03.027","type":"journal-article","created":{"date-parts":[[2013,3,30]],"date-time":"2013-03-30T13:38:34Z","timestamp":1364650714000},"page":"358-366","source":"Crossref","is-referenced-by-count":102,"title":["Established and new-generation antithrombotic drugs in patients with cirrhosis \u2013 Possibilities and caveats"],"prefix":"10.1016","volume":"59","author":[{"given":"Ton","family":"Lisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter W.","family":"Kamphuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Northup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.03.027_b0005","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2013.03.027_b0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.03.027_b0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1538-7836.2011.04429.x","article-title":"Hypercoagulability in cirrhosis: causes and consequences","volume":"9","author":"Tripodi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2007.02772.x","article-title":"Hypercoagulation and thrombophilia in liver disease","volume":"6","author":"Northup","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0025","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2010.01.042","article-title":"Hemostasis and thrombosis in patients with liver disease: the ups and downs","volume":"53","author":"Lisman","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.03.027_b0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2036.2009.04182.x","article-title":"Systematic review: portal vein thrombosis in cirrhosis","volume":"31","author":"Tsochatzis","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.03.027_b0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/TP.0b013e31826e8e53","article-title":"Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review","volume":"94","author":"Rodriguez-Castro","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.03.027_b0040","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.03.027_b0045","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.03.027_b0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.03.027_b0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cld.2008.09.013","article-title":"Parenchymal extinction: coagulation and hepatic fibrogenesis","volume":"13","author":"Anstee","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2013.03.027_b0065","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.03.027_b0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.44.2.270","article-title":"Anti-inflammatory drugs and variceal bleeding: a case-control study","volume":"44","author":"De Ledinghen","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.03.027_b0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"Sogaard","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0080","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","article-title":"Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism","volume":"101","author":"Northup","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-9560-9-1","article-title":"The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients","volume":"9","author":"Aldawood","year":"2011","journal-title":"Thromb J"},{"key":"10.1016\/j.jhep.2013.03.027_b0090","first-page":"259","article-title":"Venous thromboembolism and liver cirrhosis","volume":"100","author":"Garcia-Fuster","year":"2008","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jhep.2013.03.027_b0095","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2013.03.027_b0100","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jhep.2013.03.027_b0105","first-page":"1253a","article-title":"Prophylactic anticoagulation for deep venous thrombosis in hospitalized cirrhosis patients is safe and does not lead to increased bleeding events","volume":"54","author":"Intagliata","year":"2011"},{"key":"10.1016\/j.jhep.2013.03.027_b0110","first-page":"211","article-title":"Stroke-cirrhosis relationship: an autopsy study in a heavy drinking population","volume":"23","author":"Melato","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0002-8703(60)90192-7","article-title":"The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: a review of 639 cases of cirrhosis of the liver from 17,731 autopsies","volume":"60","author":"Howell","year":"1960","journal-title":"Am Heart J"},{"key":"10.1016\/j.jhep.2013.03.027_b0120","first-page":"655","article-title":"Cardiovascular disease in cirrhosis \u2013 a point-prevalence study in relation to glucose tolerance","volume":"94","author":"Marchesini","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10620-009-0738-z","article-title":"Coronary artery disease in patients with liver cirrhosis","volume":"55","author":"Kalaitzakis","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2013.03.027_b0130","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.amjcard.2011.07.013","article-title":"Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease","volume":"108","author":"Patel","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2013.03.027_b0135","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/lt.21540","article-title":"Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation","volume":"14","author":"McAvoy","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.03.027_b0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cld.2009.07.005","article-title":"Epidemiology and natural history of non-alcoholic steatohepatitis","volume":"13","author":"Argo","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2013.03.027_b0145","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/gut.2007.144550","article-title":"Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease","volume":"57","author":"Fujita","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.03.027_b0150","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21779","article-title":"Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice","volume":"46","author":"Ganey","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.027_b0155","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1538-7836.2008.03015.x","article-title":"Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies","volume":"6","author":"Anstee","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0160","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gut.52.8.1206","article-title":"Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection","volume":"52","author":"Wright","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.03.027_b0165","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1572-0241.2007.01223.x","article-title":"Are chronic hepatitis C viral infections more benign in patients with hemophilia?","volume":"102","author":"Assy","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0170","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0049-3848(11)70017-2","article-title":"Resistance to anti-platelet agents","volume":"127","author":"Cattaneo","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhep.2013.03.027_b0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2008.09.010","article-title":"The platelet and platelet function testing in liver disease","volume":"13","author":"Hugenholtz","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2013.03.027_b0180","first-page":"1380","article-title":"Appropriate aspirin use for primary prevention of cardiovascular disease","volume":"83","author":"Miser","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jhep.2013.03.027_b0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","author":"European Association for the Study of the Liver","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.03.027_b0190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182371258","article-title":"Coronary artery stents and antiplatelet therapy in patients with cirrhosis","volume":"46","author":"Russo","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0195","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","article-title":"Antiplatelet agents for the treatment and prevention of atherothrombosis","volume":"32","author":"Patrono","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2013.03.027_b0200","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y(12) inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2013.03.027_b0205","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/00912700022008973","article-title":"Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel","volume":"40","author":"Slugg","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.03.027_b0210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2710.2009.01067.x","article-title":"Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jhep.2013.03.027_b0215","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0091270010379409","article-title":"Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment","volume":"51","author":"Butler","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.03.027_b0220","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/hep.510240417","article-title":"Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole","volume":"24","author":"Wanless","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.027_b0225","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1572-0241.1998.00429.x","article-title":"Beneficial hemodynamic effects of dipyridamole on portal circulation in cirrhosis","volume":"93","author":"Sansoe","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.03.027_b0230","first-page":"59","article-title":"Effect of dipyridamole on kidney function in cirrhosis","volume":"17","author":"Llach","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.027_b0235","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0140-6736(12)60409-7","article-title":"Heparin-induced skin lesions","volume":"380","author":"Schindewolf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.03.027_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.03.027_b0245","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1538-7836.2012.04824.x","article-title":"Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis","volume":"10","author":"Senzolo","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0250","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1478-3231.2011.02489.x","article-title":"Towards a rational use of low-molecular-weight heparin in patients with cirrhosis","volume":"31","author":"Lisman","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.03.027_b0255","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1538-7836.2010.03877.x","article-title":"Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease","volume":"8","author":"Tripodi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0260","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1600-6143.2010.03064.x","article-title":"The international normalized ratio (INR) in the MELD score: problems and solutions","volume":"10","author":"Porte","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.03.027_b0265","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1478-3231.2008.01783.x","article-title":"Interlaboratory variability in assessment of the model of end-stage liver disease score","volume":"28","author":"Lisman","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.03.027_b0270","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hep.21732","article-title":"The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation","volume":"46","author":"Tripodi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.03.027_b0275","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2013.03.027_b0280","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2011-10-378950","article-title":"How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch","volume":"119","author":"Schulman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2013.03.027_b0285","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.03.027_b0290","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.03.027_b0295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2013.03.027_b0300","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jhep.2013.03.027_b0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0310","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.03.027_b0315","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2013.03.027_b0320","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2013 a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhep.2013.03.027_b0325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2013.03.027_b0330","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.03.027_b0335","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T19:06:52Z","timestamp":1688152012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0168827813002067"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.03.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}